HBV垂直傳播形式及阻斷策略

參考文獻

［1］JIA Y, LI L, LI XG, et al. Analysis of antiviral regimen in outpatients with chronic hepatitis B［J］. Chin J Clin Pharmacol, 2017, 33(22): 2308-2310. (in Chinese)

賈瑩, 李璐, 李曉光, 等. 慢性乙型病毒性肝炎患者抗病毒藥物使用情況分析［J］. 中國臨床藥理學雜誌, 2017, 33(22): 2308-2310.

［2］LIU YL, KUANG JQ, ZHANG R, et al. Analysis about clinical data of intrauterine infection of hepatitis B virus［J］. Chin J Obstetr Gynecol, 2002, 37(8): 465-468.（in Chinese）

劉穎琳, 鄺健全, 張睿, 等.胎兒感染乙型肝炎病毒的臨床研究［J］. 中華婦產科雜誌, 2002, 37(8): 465-468.

［3］SARIN SK, KUMAR M, SHRIVASTAVA S, et al. Influence of chronic HBV infection on pregnancy: A human model of maternofetal virus host interactions［J］. Gastroenterology, 2011, 141(4): 1522-1525.

［4］BAI H, ZHANG L, MA L, et al. Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism［J］. World J Gastroenterol, 2007, 13(26): 3625-3630.

［5］LIN HH, LEE TY, CHEN DS, et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus［J］. J Pediatr, 1987, 111(6 Pt 1): 877-881.

［6］YI W, PAN CQ, HAO JZ, et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers［J］. J Hepatol, 2014, 60(3): 523-529.

［7］BAI GQ, LI SH, YUE YF, et al. The study on role of peripheral blood mononuclear cell in HBV intrauterine infection［J］. Arch Gynecol Obstet, 2011, 283(2): 317-321.

［8］WONG VC, LEE AK, IP HM. Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant［J］. Br J Obstet Gynaecol, 1980, 87(11): 958-965.

［9］PAO CC, YAO DS, LIN MY, et al. Hepatitis B virus DNA in cervicovaginal cells［J］. Arch Pathol Lab Med, 1991, 115(6): 607-609.

［10］BEASLEY RP, STEVENS CE, SHIAO IS, et al. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B［J］. Lancet, 1975, 2(7938): 740-741.

［11］LI XM, SHI MF, YANG YB, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection［J］. World J Gastroenterol, 2004, 10(21): 3215-3217.

［12］HAN GR, CAO MK, ZHAO W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection［J］. J Hepatol, 2011, 55(6): 1215-1221.

［13］HAN L, ZHANG HW, XIE JX, et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus［J］. World J Gastroenterol, 2011, 17(38): 4321-4333.

［14］CHEN HL, LEE CN, CHANG CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus［J］. Hepatology, 2015, 62(2): 375-386.

［15］ZHANG H, PAN CQ, PANG Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice［J］. Hepatology, 2014, 60(2): 468-476.

［16］HAN GR, JIANG HX, YUE X, et al. Efficacy and safety of telbivudine treatment: An open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection［J］. J Viral Hepat, 2015, 22(9): 754-762.

［17］PIRATVISUTH T, HAN GR, POL S, et al. Comprehensive review of telbivudine in pregnant women with chronic hepatitis B［J］. World J Gastroenterol, 2016, 8(9): 452-460.

［18］BRIDGES EG, SELDEN JR, LUO S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B［J］. Antimicrob Agents Chemother, 2008, 52(7): 2521-2528.

［19］LIU M, CAI H, YI W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy［J］. J Viral Hepat, 2013, 20(Suppl 1): 65-70.

［20］ter BORG MJ, LEEMANS WF, de MAN RA, et al. Exacerbation of chronic hepatitis B infection after delivery［J］. J Viral Hepat, 2008, 15(1): 37-41.

［21］APASL consensus group for the treatment of chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update［J］. J Clin Hepatol, 2012, 28(8): Ⅰ-ⅩⅩⅠ. (in Chinese)

亞太肝病學會慢性乙型肝炎治療共識工作組. 亞太地區慢性乙型肝炎治療共識(2012最新版)［J］. 臨床肝膽病雜誌, 2012, 28(8): Ⅰ-ⅩⅩⅠ.

［22］ZHU Q, YU G, YU H, et al. A randomized control trial on interruption of HBV transmission in uterus［J］. Chin Med J (Engl), 2003, 116(5): 685-687.

［23］YUE Y, YANG X, ZHANG S. Prevention of intrauterine infection by hepatitis B virus with hepatitis B immune globulin: Efficacy and mechanism［J］. Chin Med J (Engl), 1999, 112(1): 37-39.

［24］YUAN J, LIN J, XU A, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: A single-centre randomized study［J］. J Viral Hepat, 2006, 13(9): 597-604.

［25］SCHILLING R, IJAZ S, DAVIDOFF M, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions［J］. J Virol, 2003, 77(16): 8882-8892.

［26］LIANG X, BI S, YANG W, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination［J］. Vaccine, 2009, 27(47): 6550-6557.

［27］LIANG X, BI S, YANG W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China［J］. J Infect Dis, 2009, 200(1): 39-47.

［28］Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version)［J］. J Clin Hepatol, 2011, 27(1)：Ⅰ-ⅩⅥ. （in Chinese）

中華醫學會肝病學分會,中華醫學會感染病學分會.慢性乙型肝炎防治指南（2010年版）［J］.臨床肝膽病雜誌， 2011, 27(1)：Ⅰ-ⅩⅥ.

［29］Obstetrics Section， Society of Obstetrics and Gynecology， Chinese Medical Association. Clinical guidelines for prevention of mother-to-child transmission of hepatitis B virus (1st Edition)［J］. Chin J Obstetr Gynecol, 2013, 48(2): 151-154.（in Chinese）

中華醫學會婦產科學分會產科學組. 乙型肝炎病毒母嬰傳播預防臨床指南(第1版)［J］. 中華婦產科雜誌, 2013, 48(2): 151-154.

［30］CHEN HL, LIN LH, HU FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV［J］. Gastroenterology, 2012, 142(4): 773-781.

［31］ZOU H, CHEN Y, DUAN Z, et al. Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers［J］. PLoS One, 2011, 6(10): e26748.

［32］KUBO A, SHLAGER L, MARKS AR, et al. Prevention of vertical transmission of hepatitis B: An observational study［J］. Ann Intern Med, 2014, 160(12): 828-835.

［33］LIN X, GUO Y, ZHOU A, et al. Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population: A hospital-based study and a meta-analysis［J］. Pediatr Infect Dis J, 2014, 33(9): 897-903.

［34］WANG JS, CHEN H, ZHU QR. Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers［J］. World J Gastroenterol, 2005, 11(23): 3582-3585.

［35］KANG W, DING Z, SHEN L, et al. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China［J］. Vaccine, 2014, 32(27): 3362-3366.

［36］FAN XH, HU YL, ZHU HL. Study on YMDD mutation during Lamivudine therapy of chronic hepatitis B［J］. J Clin Hepatol，2009, 25（3）：192-194. (in Chinese)

樊曉紅， 胡玉琳， 朱紅玲. 拉米夫定治療慢性乙型肝炎發生YMDD變異的研究［J］. 臨床肝膽病雜誌， 2009, 25（3）：192-194.

［37］LIU JH, JIANG PR. Prevention of vertical transmission of hepatitis B virus from mother to child in perinatal period［J/CD］. Chin J Obstet Emerg：Electronic Edition， 2017, 6(3): 175-179. (in Chinese)

劉晶華, 蔣佩茹. 圍產期乙型肝炎病毒母嬰垂直傳播的防治［J/CD］. 中華產科急救電子雜誌, 2017， 6(3): 175-179．

［38］CADRANEL S, ZEGHLACHE S, FERNANDEZ S, et al. Vaccination of newborns of HBsAg-positive carrier mothers with a recombinant DNA hepatitis B vaccine［J］. Postgrad Med J, 1987, 63(Suppl 2): 159-160.

［39］HALLIDAY ML, KANG LY, RANKIN JG, et al. An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China［J］. Int J Epidemiol, 1992, 21(3): 564-573.

［40］Centers for Disease Control and Prevention (CDC). Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data—United States［J］. MMWR Morb Mortal Wkly Rep, 2011, 60(13): 410-413.

［41］MAST EE, MARGOLIS HS, FIORE AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: Immunization of infants, children, and adolescents［J］. MMWR Recomm Rep, 2005, 54(RR-16): 1-31.

［42］WHO Publication. Hepatitis B vaccines: WHO position paper-recommendations［J］. Vaccine, 2010, 28(3): 589-590.

［43］ZOU H, CHEN Y, DUAN Z, et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers［J］. J Viral Hepat, 2012, 19(2): e18-e25.

［44］WEN WH, CHANG MH, ZHAO LL, et al. Mother-to-infant transmission of hepatitis B virus infection: Significance of maternal viral load and strategies for intervention［J］. J Hepatol, 2013, 59(1): 24-30.

［45］DANIELSSON N, FAKAKOVIKAETAU T, SZEGEDI E. Improved immunization practices reduce childhood hepatitis B infection in Tonga［J］. Vaccine, 2009, 27(33): 4462-4467.

［46］BOOT HJ, HAHNE S, CREMER J, et al. Persistent and transient hepatitis B virus (HBV) infections in children born to HBV-infected mothers despite active and passive vaccination［J］. J Viral Hepat, 2010, 17(12): 872-878.

［47］LUONGO M, CRITELLI R, GROTTOLA A, et al. Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: Sequence analysis and therapeutic strategy［J］. J Clin Virol, 2015, 62: 89-91.

［48］CHONG-JIN O, WEI NING C, SHIUAN K, et al. Identification of hepatitis B surface antigen variants with alterations outside the 「a」 determinant in immunized Singapore infants［J］. J Infect Dis, 1999, 179(1): 259-263.

［49］ADKINS B, LECLERC C, MARSHALL-CLARKE S. Neonatal adaptive immunity comes of age［J］. Nat Rev Immunol, 2004, 4(7): 553-564.

［50］ELAHI S, ERTELT JM, KINDER JM, et al. Immunosuppressive CD71 erythroid cells compromise neonatal host defence against infection［J］. Nature, 2013, 504(7478): 158-162 .

［51］BEASLEY RP, HWANG LY, LEE GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine［J］. Lancet, 1983, 2(8359): 1099-1102.

［52］MILICH DR, JONES JE, HUGHES JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?［J］. Proc Natl Acad Sci U S A, 1990, 87(17): 6599-6603.

［53］PUBLICOVER J, GAGGAR A, NISHIMURA S, et al. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B［J］. J Clin Invest, 2013, 123(9): 3728-3739.

［54］KENNEDY PTF, SANDALOVA E, JO J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B［J］. Gastroenterology, 2012, 143(3): 637-645.

［55］GIBBONS D, FLEMING P, VIRASAMI A, et al. Interleukin-8 (CXCL8) production is a signatory T cell effector function of human newborn infants［J］. Nat Med, 2014, 20(10): 1206-1210.

［56］HONG M, SANDALOVA E, LOW D, et al. Trained immunity in newborn infants of HBV-infected mothers［J］. Nat Commun, 2015, 6: 6588.

點擊下方「閱讀原文」，下載本文完整PDF

引證本文：趙斐,劉菲,王中峰,等. HBV垂直傳播形式及阻斷策略[J]. 臨床肝膽病雜誌, 2019, 35(11): 2557-2560.

本文編輯：朱晶

公眾號編輯：邢翔宇